At IAG, we leverage our core expertise in medical image analysis and trial design. We work closely with our clients to understand the specifics of their therapeutic agents, so that we can deploy optimal study-specific image scoring methodologies.

Medical Imaging based biomarkers play critical role in early understanding of therapeutic efficacy and patients’ response to the treatment. The choice of MRI, CT, PET or more complex imaging modalities should be specific to the Mechanism of Action, new treatment manifestations, the timing of the imaging visits and study desired outcomes.

When chosen smartly, imaging endpoints can greatly support trial enrichment through patient stratification, provide information of early efficacy and safety, allow to make go/no-go decisions objectively and often predict drug responses at much earlier timepoint.

When it comes to the assessment of efficacy of the drug combinations and development of advanced therapies, the imaging allows reliably and non-invasively monitor short-, mid- and long-term therapeutic outcomes.

Which imaging biomarker to use in your trial will depend on which questions need to be answered. Read more about particular therapeutic areas and the relevant biomarkers.

In early drug development phases, we tend to use more advanced imaging (MRI, PET, multi-modality imaging) to answer specific questions around whether the new drug candidate reaches the target and, if so, in sufficient quantity or whether the expected mechanism of action can be observed.

We deploy a number of our proprietary and state-of-the art methodologies, including those based on AI and Machine Learning. When planning a trial, one must make critical choices on how to use imaging and link imaging and clinical outcomes.

IAG’s expert team supports the use of state-of-the-art and advanced quantitative image reading as well as the deployment of radiomics and multi-omics strategies.

IAG’s platform DYNAMIKA and experienced project management team allow to execute trials with complex designs and advanced endpoints.

Our goal is to accelerate drug development, de-risk trial execution and to ensure integrity and scientific credibility of your data.

We take a holistic approach to the development of a clinical asset: from the strategic positioning, development of a protocol which address the study objectives and the company’s financial health to planning of a bespoke route-to-market, the investment.

Multi-dimensional views of live trial delivery and real time information access give our clients comfort that the trial is being properly conducted and dramatically accelerates the due diligence process.

We guarantee high level of efficiency in trial delivery achieved through automation of the clinical trial processes, intelligent management of all stakeholders and reduction of human error.

Our experienced team will deliver

For over a decade, we have managed successful engagements for organizations including:

• Biotech—both startups and mature organizations
• Biopharma—seeking to both in-license and out-license
• Device companies—looking to get their product to market
• Not-for-profit organizations sponsoring clinical trials
• Life sciences firms in need of business consulting and funding
• Clinical Research Organizations looking for integration
• Investors and corporate strategic funds seeking opportunities to capture upside value in late-stage drugs

We closely work with many CRO and CMO partners to who share our philosophy of risk sharing with our clients and able to support advanced methodologies for patient stratification, ensure faster enrolment and robust patient retention.